Myeloid cell engager
Sanofi returns to Dren Bio for another B‑cell depletion therapy with $100M upfront
Sanofi; Dren Bio; B-cell depletion; autoimmune diseases; strategic collaboration; bispecific antibody; myeloid cell engager; immunology; $100M upfront; licensing deal
Sanofi Expands Immunology Pipeline with $600M Acquisition of Dren Bio’s Novel B-Cell Depleting Bispecific Antibody
Bispecific antibody, Myeloid cell engager, B-cell depletion, Autoimmune diseases, Immunology pipeline, Phagocytosis, CD20-directed therapy